[Campaign against radio-xerostomia].
The radiation induced xerostomia is a common and, up to now, irreversible side effect of the definitive or postoperative treatment of ENT cancers. A possible mechanism is the apoptosis of serous gland cells. The sequelae of xerostomia are increasing cavities, plaques and parodontosis, infections in the pharynx, taste alterations and weight loss. Therapeutic approaches include improved oral hygiene, dietetic adjustments, artificial saliva and most recently, medication. Pilocarpine, a parasympathomimeticum, results in a degranulation of the secretoric granula and consequently, lowers the radiosensitivity of the cells. Amifostine acts a scavenger of radicals and is concurrently tested in a phase III clinical trial to evaluate the selective protection of normal tissue during radiotherapy.
Beer
K T
KT
Klinik für Radio-Onkologie mit Abteilung für Medizinische Strahlenphysik, Universität Bern, Inselspital.
D002986:Clinical Trials as Topic; D006801:Humans; D010039:Otorhinolaryngologic Neoplasms / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D011832:Radiation Injuries / Q000517:prevention & control*; D018714:Radiotherapy, Adjuvant; D012469:Salivary Glands / Q000528:radiation effects*; D014987:Xerostomia / Q000517:prevention & control*